Rigor Reviewed

Rigor-Reviewed Manuscript

Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.

Name: Αlpha¹ Rigor Record — Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Item: Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.
Rating: 100
Author: Αlpha¹

De Laere B, Crippa A, Discacciati A, Larsson B, Persson M, Johansson S, D'hondt S, Bergström R, Chellappa V, Mayrhofer M, Banijamali M, Kotsalaynen A, Schelstraete C, Vanwelkenhuyzen JP, Hjälm-Eriksson M, Pettersson L, Ullén A, Lumen N, Enblad G, Thellenberg Karlsson C, Jänes E, Sandzén J, Schatteman P, Nyre Vigmostad M, Olsson M, Ghysel C, Sautois B, De Roock W, Van Bruwaene S, Anden M, Verbiene I, De Maeseneer D, Everaert E, Darras J, Aksnessether BY, Luyten D, Strijbos M, Mortezavi A, Oldenburg J, Ost P, Eklund M, Grönberg H, Lindberg J

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 3 high issues for “Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

CitationsCitations & links (capped) ×8−1★
IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★

Citations & links are capped at −1★ combined, however many are flagged.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No reported statistical tests were found to recompute.

Problems surfaced4 types

Overstated conclusions2

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Broken references and links1

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

References not resolvable to a published paperRecomputed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The paper is a well-conducted, biomarker-driven adaptive platform trial with strong methodological rigor, clear reporting of ethics, data/code availability, and statistical methods. Minor gaps include lack of explicit reporting guideline, missing race/ethnicity data, and unverified model assumptions, but these do not undermine the overall validity.

Both reviewers classified the study as interventional; no divergence. The evaluation covered the full text, with N/A for animal-related and bench-resource criteria. The statistics verification component found no recomputable tests, so statistical correctness is not claimed beyond what was reported. The integrity check flagged retrospective registration (submitted after study start), which is a transparency concern but not a validity threat.

8 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions8 pass

The introduction cites prior retrospective analyses suggesting varying therapeutic benefits by tumor genotype, acknowledges the small number of predictive biomarkers, and describes the limitations of traditional clinical trials in evaluating biomarker-treatment combinations. The rationale for the ProBio platform trial is logically linked to these gaps, and the paper explains how the adaptive design and prospective ctDNA profiling address prior limitations.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a strong scientific premise by citing prior research on biomarker-driven treatment effects and the need for platform trials, and clearly links this to the study's objectives.

Evidence

paraphrase[Main, paragraph 1]

“Retrospective analyses suggest that different tumor genotypes yield varying therapeutic benefits.”

paraphrase[Main, paragraph 3]

“A knowledge gap in treatment of men with mCRPC is that randomized data to support which of the two main treatment classes, that is, taxanes and ARPIs, provide superior outcomes or to guide treatment decisions are limited and restricted to selected patients with mCRPC who have a poor prognosis.”

paraphrase[Main, paragraph 2]

“In contrast to traditional trials, platform trials provide an effective means to evaluate and screen for novel biomarker–treatment combinations.”

PASSReviewer 2· 95% conf

The paper clearly establishes the scientific premise by citing prior work on the heterogeneity of mCRPC, the need for biomarker-driven trials, and the limitations of traditional two-armed trials in precision oncology.

Evidence

paraphrase[Main, paragraph 1-3]

“Retrospective analyses suggest that different tumor genotypes yield varying therapeutic benefits... traditional clinical trials have not been biomarker-driven and have not focused on prospectively investigating patient subgroups to identify patients who benefit more from a specific treatment.”

paraphrase[Main, paragraph 3-4]

“The advent of precision oncology... necessitates development of clinical trials that can accommodate this consequential multiplicative hypothesis testing scenario.”

direct quote[Main, paragraph 4-5]

“ProBio uses a number of design elements to maximize the information gained from each patient entering the trial in order to rapidly sieve through multiple hypotheses.”